Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25873178 | 0.84 | ALDH1A1 (0.39) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL16218719 | 0.79 | CYP3A4 (0.44) | CYP3A4CASP6LMNAPOLBHPGD | |
| SCHEMBL16218710 | 0.76 | CYP3A4 (0.44) | CYP3A4CASP6LMNAPOLBHPGD | |
| SCHEMBL25873153 | 0.75 | ALDH1A1 (0.39) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL15126735 | 0.73 | S100A4 (0.41) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL25873092 | 0.71 | MAPT (0.39) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL22601489 | 0.71 | LMNA (0.41) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL15127056 | 0.70 | S100A4 (0.41) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL3466137 | 0.70 | KMT2A (0.44) | CYP3A4LMNAPOLBHPGDMEN1 | |
| SCHEMBL16218713 | 0.69 | PARP14 (0.43) | CYP3A4LMNAPOLBHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | INTS9, INF2, CYBA | CYP3A4 265/4885CASP6 1094/4885LMNA 389/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | CYP3A4 3999/4885CASP6 4070/4885LMNA 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.